WHITEHAWK THERAPEUTICS INC (WHWK) Stock Price & Overview
NASDAQ:WHWK • US00032Q1040
Current stock price
The current stock price of WHWK is 4.2 USD. Today WHWK is down by -0.71%. In the past month the price increased by 15.07%. In the past year, price increased by 189.66%.
WHWK Key Statistics
- Market Cap
- 198.24M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.73
- Dividend Yield
- N/A
WHWK Stock Performance
WHWK Stock Chart
WHWK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to WHWK. When comparing the yearly performance of all stocks, WHWK is one of the better performing stocks in the market, outperforming 97.12% of all stocks.
WHWK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to WHWK. While WHWK has a great health rating, there are worries on its profitability.
WHWK Earnings
WHWK Forecast & Estimates
11 analysts have analysed WHWK and the average price target is 5.78 USD. This implies a price increase of 37.62% is expected in the next year compared to the current price of 4.2.
For the next year, analysts expect an EPS growth of 17.46% and a revenue growth -100% for WHWK
WHWK Groups
Sector & Classification
WHWK Financial Highlights
Over the last trailing twelve months WHWK reported a non-GAAP Earnings per Share(EPS) of -1.73. The EPS increased by 26.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.66% | ||
| ROE | -15.11% | ||
| Debt/Equity | 0 |
WHWK Ownership
WHWK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.808B | ||
| AMGN | AMGEN INC | 15.1 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.53 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About WHWK
Company Profile
Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 23 full-time employees. The company went IPO on 2018-06-26. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Company Info
IPO: 2018-06-26
WHITEHAWK THERAPEUTICS INC
2 Headquarters Plaza, East Building, 11Th Floor
Morristown NEW JERSEY US
Employees: 23
Phone: 15513212234
WHITEHAWK THERAPEUTICS INC / WHWK FAQ
What does WHWK do?
Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 23 full-time employees. The company went IPO on 2018-06-26. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
What is the stock price of WHITEHAWK THERAPEUTICS INC today?
The current stock price of WHWK is 4.2 USD. The price decreased by -0.71% in the last trading session.
What is the dividend status of WHITEHAWK THERAPEUTICS INC?
WHWK does not pay a dividend.
How is the ChartMill rating for WHITEHAWK THERAPEUTICS INC?
WHWK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does WHITEHAWK THERAPEUTICS INC belong to?
WHITEHAWK THERAPEUTICS INC (WHWK) operates in the Health Care sector and the Biotechnology industry.
What is WHITEHAWK THERAPEUTICS INC worth?
WHITEHAWK THERAPEUTICS INC (WHWK) has a market capitalization of 198.24M USD. This makes WHWK a Micro Cap stock.
Can you provide the ownership details for WHWK stock?
You can find the ownership structure of WHITEHAWK THERAPEUTICS INC (WHWK) on the Ownership tab.